Healthcare & Life Sciences in the U.S. – Outlook 2025

The Bounce Back: Unlocking the Healthcare and Life Science Industry’s Potential in a Time of Change

In the fourth edition of FTI Consulting’s U.S. Healthcare and Life Sciences Outlook Survey, healthcare and biopharmaceutical organizations are embracing a new sense of optimism. This is a significant finding given the immense change over the past 12 months — Republicans taking control of both the United States executive and legislative branches of government and increasing use of artificial intelligence (“AI”) in drug discovery and development — and challenges affecting not only their businesses but the world in which they operate, including drug pricing concerns and continued geopolitical tensions across the globe, just to name a few.

Click here to download the full Healthcare & Life Sciences in the U.S. – Outlook 2025 report

The views expressed herein are those of the author(s) and not necessarily the views of FTI Consulting, Inc., its management, its subsidiaries, its affiliates, or its other professionals.

Related Insights

Published

January 20, 2025

temp Key Contacts

Lauren Crawford Shaver

Senior Managing Director, Head of Americas Healthcare & Life Sciences

Jim Polson

Senior Managing Director

Robert Stanislaro

Senior Managing Director

Jamie Singer

Senior Managing Director

Downloads

Most Popular Insights

  1. 2026 Private Equity Value Creation Index
  2. Payment Firms Under Scrutiny
  3. Many Global Consumers Are Avoiding the U.S.
  4. Why Isn’t There More Concern About Recession Risk?
  5. Corporate Sustainability Report

Sign up to get access to FTI Consulting Insights

Subscribe